CPIX Cumberland Pharmaceuticals Inc

  1. Stocks
  2. Healthcare
  3. NASDAQ: CPIX

Price (delayed)

$5.81

Market cap

$87.05M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$0.49

Enterprise value

$90.6M

?
Relative Growth: Rel. Growth: 6
Relative Strength: Rel. Strength: 85
Relative Valuation: Rel. Valuation: 21
Relative Profitability: Rel. Profitability: 25

Cumberland Emerging Technologies, Inc.(www.cet-fund.com)is a joint initiative between Cumberland Pharmaceuticals Inc., Vanderbilt University, LaunchTN and WinHealth Pharma. The mission of CET is to bring biomedical technologies and products conceived at ...

Highlights
The company's debt rose by 39% YoY but it fell by 4.6% QoQ
The revenue has contracted by 6% from the previous quarter but it has grown by 2.1% YoY
The net income has shrunk by 160% QoQ and by 125% YoY
Cumberland Pharmaceuticals's EPS has plunged by 158% from the previous quarter and by 96% YoY
Sector: Healthcare
Industry: Drug Manufacturers - Specialty & Generic
Website: http://www.cumberlandpharma.com
Peers: IRWD MRK PFE

Key stats

What are the main financial stats of CPIX

CPIX stock price

How has the Cumberland Pharmaceuticals stock price performed over time
Intraday
3.57%
1 week
-2.84%
1 month
28.26%
1 year
5.06%
YTD
45.98%
QTD
78.77%

Financial performance

How have Cumberland Pharmaceuticals's revenue and profit performed over time
Revenue
$41.94M
Gross profit
$34.76M
Operating income
-$7.21M
Net income
-$7.38M
Gross margin
82.9%
Net margin
-17.6%
The company's net margin has shrunk by 175% QoQ and by 120% YoY
The company's operating margin has shrunk by 173% QoQ and by 115% YoY
The net income has shrunk by 160% QoQ and by 125% YoY
CPIX's operating income has dropped by 158% since the previous quarter and by 121% year-on-year

Price vs fundamentals

How does CPIX's price correlate with its fundamentals

Growth

What is Cumberland Pharmaceuticals's growth rate over time

Valuation

What is Cumberland Pharmaceuticals stock price valuation
P/E
N/A
P/B
4.02
P/S
2.07
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
2.16
Cumberland Pharmaceuticals's EPS has plunged by 158% from the previous quarter and by 96% YoY
CPIX's P/B is 85% above its last 4 quarters average of 2.1
CPIX's equity is down by 24% year-on-year and by 13% since the previous quarter
The stock's price to sales (P/S) is 100% more than its 5-year quarterly average of 1.0 and 67% more than its last 4 quarters average of 1.2
The revenue has contracted by 6% from the previous quarter but it has grown by 2.1% YoY

Efficiency

How efficient is Cumberland Pharmaceuticals business performance
CPIX's return on invested capital has dropped by 188% since the previous quarter
The company's return on equity has shrunk by 179% QoQ and by 129% YoY
The ROA has plunged by 163% from the previous quarter and by 139% YoY
Cumberland Pharmaceuticals's ROS has plunged by 154% YoY

Dividends

What is CPIX's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for CPIX.

Financial health

How did Cumberland Pharmaceuticals financials performed over time
The total assets is 43% greater than the total liabilities
The quick ratio has decreased by 27% YoY and by 5% QoQ
The current ratio is down by 24% year-on-year and by 6% since the previous quarter
The company's debt is 33% lower than its equity
The debt to equity has soared by 86% YoY and by 10% from the previous quarter
The company's debt rose by 39% YoY but it fell by 4.6% QoQ

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.